Treatments that targets the PD-1 pathway have been investigated in various solid tumors, such as melanoma, non-small-cell lung cancer, breast cancer, colorectal cancer, renal cell carcinoma, ovarian cancer and hematologic malignancies [39,40,41,42]. This evidence concerns the gene PDCD1 and breast carcinoma.